tradingkey.logo

BUZZ-Harrow rises after H.C. Wainwright starts coverage with 'buy' rating

ReutersFeb 6, 2025 3:30 PM

Eye-drug maker Harrow's HROW shares rise 2.09% to $31.32

Brokerage H.C. Wainwright starts coverage on HROW with "buy" rating; sets PT at $57

Brokerage sees rapid growth driven by co's branded products for eye diseases

Expects HROW to continue to make meaningful and sensible buys

Says its eye drop Vevye compares well to other dry eye treatments

Says that other eye products that are used during surgical procedures such as Iheezo and Triesence also serve as growth drivers

The PT is a 84.5% upside to the stock's last close

Stock rose ~232% in the last 12 months

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI